Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10919717 | 0.84 | P2RX7 (0.47) | P2RX7 | |
| SCHEMBL1266807 | 0.83 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL3294851 | 0.77 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL10297724 | 0.77 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL30456214 | 0.77 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL23003303 | 0.77 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL14661116 | 0.77 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL15770262 | 0.77 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL10297567 | 0.77 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL15129300 | 0.75 | P2RX7 (0.59) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4244224-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2023-09-20 | — | — | EP | disclosed |
| US-20220213076-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| US-20220213076-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| WO-2022104348-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-19 | — | — | WO | disclosed |
| US-11312709-B2 | Ghrelin O-acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-26 | — | — | US | disclosed |
| US-11312709-B2 | Ghrelin O-acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-26 | — | — | US | disclosed |
| US-20210053955-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-25 | — | — | US | disclosed |
| US-20210053955-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-25 | — | — | US | disclosed |
| EP-3749304-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019149959-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | WO | disclosed |
| US-5541334-A | TREATING HIV | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0327239-B1 | 1-carbacephalosporin antibiotics | LILLY CO ELI (US) | 1994-06-22 | — | — | EP | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
| US-5019571-A | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1991-05-28 | — | — | US | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4902707-A | Bicyclic pyrazolidinones, compositions and use | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
| EP-0327239-A1 | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213076-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | MBOAT4, GIPR, GPR119 | P2RX7 4881/4885 |
| US-11312709-B2 | Ghrelin O-acyltransferase inhibitors | MBOAT4, GIPR, GPR119 | P2RX7 4881/4885 |
| US-20210053955-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | MBOAT4, GIPR, GPR119 | P2RX7 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.